| Patents for A61P 9 - Drugs for disorders of the cardiovascular system (159,484) |
|---|
| 03/07/2002 | CA2420832A1 Methods and reagents for protease inhibition |
| 03/07/2002 | CA2420765A1 Anti-angiogenic peptides |
| 03/07/2002 | CA2420696A1 Isolated human drug-metabolizing proteins, nucleic acid molecules and uses thereof |
| 03/07/2002 | CA2420667A1 Quinoline-(c=o)-(di-,tri- and tetrapeptide) derivatives as caspase inhibitors |
| 03/07/2002 | CA2420659A1 Genes expressed in the cell cycle |
| 03/07/2002 | CA2420652A1 Vertebrate intestinal protein which absorbs cholesterol, and the use of this protein for identifying inhibitors of intestinal cholesterol transport |
| 03/07/2002 | CA2420591A1 Isolated human kinase proteins, nucleic acid molecules encoding human kinase proteins, and uses thereof |
| 03/07/2002 | CA2420178A1 Oxazolyl-aryloxyacetic acid derivatives and their use as ppar agonists |
| 03/07/2002 | CA2420122A1 7-oxo pyridopyrimidines |
| 03/07/2002 | CA2420103A1 Modulation of fas and fasl expression |
| 03/07/2002 | CA2420062A1 Erbb4 antagonists |
| 03/07/2002 | CA2419841A1 Novel cd40:cd154 binding interruptor compounds and use thereof to treat immunological complications |
| 03/07/2002 | CA2419699A1 Gem-substituted .alpha. v .beta. 3 integrin antagonists |
| 03/07/2002 | CA2419606A1 Lung surfactant compositions with dynamic swelling behaviour |
| 03/07/2002 | CA2419561A1 Method for treating the central nervous system by administration of igf structural analogs |
| 03/07/2002 | CA2419472A1 Sgk2 and sgk3 used as diagnostic and therapeutic targets |
| 03/07/2002 | CA2419399A1 Nucleoside derivatives for the treatment of hepatitis c |
| 03/07/2002 | CA2419342A1 G-protein coupled receptors |
| 03/07/2002 | CA2419255A1 Compounds containing a bicyclic ring system useful as alpha v beta 3 antagonists |
| 03/07/2002 | CA2419249A1 Water-dispersible encapsulated sterols |
| 03/07/2002 | CA2418041A1 Pyrrolidine derivatives and their use as chymase inhibitor |
| 03/07/2002 | CA2386552A1 Method for synthesizing flosequinan from 4-fluoroanthranilic acid |
| 03/06/2002 | EP1184465A2 Method for diagnosing polymorphisms in human MCT-1 and drugs related to such polymorphisms |
| 03/06/2002 | EP1184366A1 Substituted phenylpropionic acid derivatives as agonists to human peroxisome proliferator-activated receptor alpha(ppar) |
| 03/06/2002 | EP1184034A2 Oral drug composition containing a verapamil derivative as a drug-absorption promotor |
| 03/06/2002 | EP1183386A1 Tm4sf receptors |
| 03/06/2002 | EP1183358A1 Targeted angiogenesis |
| 03/06/2002 | EP1183357A2 Vascular endothelial growth factor dimers |
| 03/06/2002 | EP1183353A1 Modified chimeric polypeptides with improved pharmacokinetic properties |
| 03/06/2002 | EP1183352A1 Vascular endothelial growth factor variants |
| 03/06/2002 | EP1183351A1 Phospholipid transfer protein |
| 03/06/2002 | EP1183344A2 Adam polynucleotides and polypeptides |
| 03/06/2002 | EP1183333A1 Methods of using rnase p reaction mechanisms of action |
| 03/06/2002 | EP1183274A1 Method and compounds for inhibiting activity of serine elastases |
| 03/06/2002 | EP1183259A2 Azepinoindole derivatives, the production and use thereof |
| 03/06/2002 | EP1183258A1 Imidazo-containing heterocyclic compounds, their compositions and uses |
| 03/06/2002 | EP1183257A1 Triazolopyrimidinol compounds and salts thereof |
| 03/06/2002 | EP1183254A1 Substituted bicyclic heteroaryl compounds as integrin antagonists |
| 03/06/2002 | EP1183252A1 New pharmaceutically active compounds |
| 03/06/2002 | EP1183245A1 Selective npy (y5) antagonists |
| 03/06/2002 | EP1183241A1 Spiroimidazolidine derivatives, their preparation, their use and pharmaceutical preparations comprising them |
| 03/06/2002 | EP1183239A1 Aromatic sulfone hydroxamic acid metalloprotease inhibitor |
| 03/06/2002 | EP1183237A1 Novel antioxidants, preparation methods and uses |
| 03/06/2002 | EP1183236A1 Cinnamoylaminoalkyl-substituted benzenesulfonamide derivatives |
| 03/06/2002 | EP1183235A2 INHIBITORS OF FACTOR Xa |
| 03/06/2002 | EP1183234A1 INHIBITORS OF FACTOR Xa |
| 03/06/2002 | EP1183233A2 Bradykinin receptor antagonists |
| 03/06/2002 | EP1183049A2 Modification of biological elements |
| 03/06/2002 | EP1183047A2 Pharmaceutical preparation |
| 03/06/2002 | EP1183046A1 Aminotetralin derivative for the therapy of cardiovascular diseases |
| 03/06/2002 | EP1183042A2 Methods for treating diabetes |
| 03/06/2002 | EP1183039A1 Pharmaceutical preparations of bioactive substances extracted from natural sources |
| 03/06/2002 | EP1183032A1 Method of enhancing insulin action |
| 03/06/2002 | EP1183025A2 Inhibitors of proton-gated cation channels and their use in the treatment of ischaemic disorders |
| 03/06/2002 | EP1183020A2 Use of(-)(3-trihalomethylphenoxy) (4-halophenyl)acetic acid derivatives for treatment of insulin resistance, type 2 diabetes, hyperlipidaemia and hyperuricaemia |
| 03/06/2002 | EP1183019A2 Ace-2 inhibiting compounds and methods of use thereof |
| 03/06/2002 | EP1183014A1 Controlled release and taste masking oral pharmaceutical compositions |
| 03/06/2002 | EP1183011A1 Method of treating angina and/or anginal equivalents, and pharmaceutical compositions and kit related thereto |
| 03/06/2002 | EP0938505B1 Anti-endoglin monoclonal antibodies and their use in anti-angiogenesis therapy |
| 03/06/2002 | EP0876372B1 Heteroarylcarboxamide derivatives |
| 03/06/2002 | EP0760818B1 Use of tetrahydropteridine derivatives as no-synthase inhibitors |
| 03/06/2002 | CN2479952Y Nm silver plaster for trauma |
| 03/06/2002 | CN1339038A Tricyclic benzodiazepines as vasopressin receptor antagonists |
| 03/06/2002 | CN1338958A The use of 4-H-1-benzopyran-4-one derivatives as inhibitors of smooth muscle cell proliferation |
| 03/06/2002 | CN1338946A Combinations of ileal bile acid transport inhibitors and nicotinic acid derivatives for cardiovascular indications |
| 03/06/2002 | CN1338945A Combination of ileal bile acid transport inhibitors and bile acid sequestring agents for cardiovascular indications |
| 03/06/2002 | CN1338944A Cholesteryl ester transfer protein inhibitors and fibric acid derivatives for cardiovascular indications |
| 03/06/2002 | CN1338938A Use of moxonidine for postmyocardial infarction treatment |
| 03/06/2002 | CN1338936A Drug-combinations comprising (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid and an inhibitor, inducer or substrate of P450 |
| 03/06/2002 | CN1338930A Method for the prevention or reduction of cardiovascular events associated with coronary intervention |
| 03/06/2002 | CN1338929A Highly purified ethyl EPA and other EPA derivatives for psychiatric and neurological disorders |
| 03/06/2002 | CN1338923A Method for controlling liposome size |
| 03/06/2002 | CN1338305A Matrix metalloprotease tissue depressant for preventing and treating angiostenosis after damage |
| 03/06/2002 | CN1338278A Prescriptions of 12 moxibustion medicines (for carditis and encephalitis) |
| 03/06/2002 | CN1338276A Medicine for treating cardiovascular and cerebrovascular diseases and diseases in nerve network system |
| 03/06/2002 | CN1080257C Guanidine derivatives |
| 03/06/2002 | CA2356557A1 Pharmaceutical combinations for the treatment of stroke and traumatic brain injury |
| 03/06/2002 | CA2356545A1 Pharmaceutical combinations for the treatment of stroke and traumatic brain injury |
| 03/05/2002 | US6353116 Endothelin receptor antagonists |
| 03/05/2002 | US6353092 Patched-2 polypeptide |
| 03/05/2002 | US6353026 Antiinflammatory agents with polymorphone neutrophils |
| 03/05/2002 | US6353018 Compounds, their preparation and use |
| 03/05/2002 | US6353010 Enzyme inhibitors tumor necrosis factor and phosphodiesterase for antiinflammatory agents |
| 03/05/2002 | US6353003 Method for reducing levels of homocysteine and C-reactive protein |
| 03/05/2002 | US6353002 Therapeutic agents |
| 03/05/2002 | US6352992 Endothelin antagonist and beta receptor blocking agent as combined preparations |
| 03/05/2002 | US6352990 CRF receptor antagonists and methods relating thereto |
| 03/05/2002 | US6352988 High affinity for d4 receptors; treatment of schizophrenia, other psychoses, anxiety disorders, depression, alcohol abuse, impulse control disorders, aggression |
| 03/05/2002 | US6352985 Benzimidazole compounds |
| 03/05/2002 | US6352975 Methods of treating hypertension and compositions for use therein |
| 03/05/2002 | US6352971 Polypeptides with amino acid sequences |
| 03/05/2002 | US6352832 Anti-CCR2 antibodies and methods of use therefor |
| 03/05/2002 | US6352555 Methods for implanting cells |
| 03/05/2002 | CA2266565C Azabicyclic rotomase inhibitors |
| 03/05/2002 | CA2206122C Arylacrylamide derivatives |
| 03/05/2002 | CA2126465C Inhibitor for restenosis after percutaneous coronary arterioplasty |
| 02/28/2002 | WO2002016965A2 Radioactive emission detector |
| 02/28/2002 | WO2002016937A1 Method of screening remedy for heart failure |
| 02/28/2002 | WO2002016638A1 METHOD FOR IDENTIFYING SUBSTANCES USEFUL FOR TREATING INFLAMMATION USING THE RESPONSE ELEMENT TO THE IλBα ROR RECEPTOR |
| 02/28/2002 | WO2002016632A1 Pharmaceutical compositions comprising a modulator of adamts-1 |